Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 407

1.

CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies.

Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Onofrj M, Aarsland D, Bonanni L; European DLB consortium.

J Neurol Neurosurg Psychiatry. 2019 Jul 31. pii: jnnp-2019-320980. doi: 10.1136/jnnp-2019-320980. [Epub ahead of print] No abstract available.

PMID:
31366604
2.

Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation.

Rajkumar AP, Bidkhori G, Shoaie S, Clarke E, Morrin H, Hye A, Williams G, Ballard C, Francis P, Aarsland D.

Am J Geriatr Psychiatry. 2019 Jun 24. pii: S1064-7481(19)30414-2. doi: 10.1016/j.jagp.2019.06.007. [Epub ahead of print]

PMID:
31327631
3.

Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia.

Clarke E, Jantrachotechatchawan C, Buhidma Y, Broadstock M, Yu L, Howlett D, Aarsland D, Ballard C, Francis PT.

Neurochem Int. 2019 Oct;129:104502. doi: 10.1016/j.neuint.2019.104502. Epub 2019 Jul 9.

PMID:
31299418
4.

The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.

Førland MG, Tysnes OB, Aarsland D, Maple-Grødem J, Pedersen KF, Alves G, Lange J.

Eur J Neurol. 2019 Jul 10. doi: 10.1111/ene.14032. [Epub ahead of print]

PMID:
31293044
5.

Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia - A Pilot Study.

Bergland AK, Soennesyn H, Dalen I, Rodriguez-Mateos A, Berge RK, Giil LM, Rajendran L, Siow R, Tassotti M, Larsen AI, Aarsland D.

Front Genet. 2019 Jun 11;10:536. doi: 10.3389/fgene.2019.00536. eCollection 2019.

6.

ASSOCIATION OF DEPRESSIVE SYMPTOMS AND SUBJECTIVE MEMORY COMPLAINTS WITH THE INCIDENCE OF COGNITIVE IMPAIRMENT IN OLDER ADULTS WITH HIGH BLOOD PRESSURE.

Borda MG, Santacruz JM, Aarsland D, Camargo-Casas S, Cano-Gutierrez CA, Suárez-Monsalve S, Campos-Fajardo S, Pérez-Zepeda MU.

Eur Geriatr Med. 2019 Jun;10(3):413-420. doi: 10.1007/s41999-019-00185-1. Epub 2019 Apr 3.

PMID:
31186819
7.

Mediating effect of mutuality on caregiver burden in Parkinson's disease partners.

Karlstedt M, Fereshtehnejad SM, Aarsland D, Lökk J.

Aging Ment Health. 2019 May 29:1-8. doi: 10.1080/13607863.2019.1619165. [Epub ahead of print]

PMID:
31140294
8.

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression.

Pereira JB, Weintraub D, Chahine L, Aarsland D, Hansson O, Westman E.

NPJ Parkinsons Dis. 2019 May 3;5:7. doi: 10.1038/s41531-019-0079-3. eCollection 2019.

9.

GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study.

Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, Heilmann-Heimbach S, Hernández I, Moreno-Grau S, de Rojas I, Morenas-Rodríguez E, Fladby T, Sando SB, Bråthen G, Blanc F, Bousiges O, Lemstra AW, van Steenoven I, Londos E, Almdahl IS, Pålhaugen L, Eriksen JA, Djurovic S, Stordal E, Saltvedt I, Ulstein ID, Bettella F, Desikan RS, Idland AV, Toft M, Pihlstrøm L, Snaedal J, Tárraga L, Boada M, Lleó A, Stefánsson H, Stefánsson K, Ramírez A, Aarsland D, Andreassen OA.

Sci Rep. 2019 May 7;9(1):7013. doi: 10.1038/s41598-019-43458-2.

10.

The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress.

Terum TM, Testad I, Rongve A, Aarsland D, Svendsboe E, Andersen JR.

Int J Geriatr Psychiatry. 2019 May 2. doi: 10.1002/gps.5134. [Epub ahead of print]

PMID:
31050041
11.

Combinatory microRNA serum signatures as classifiers of Parkinson's disease.

Patil KS, Basak I, Dalen I, Hoedt E, Lange J, Lunde KA, Liu Y, Tysnes OB, Forsgren L, Aarsland D, Neubert TA, Larsen JP, Alves G, Møller SG.

Parkinsonism Relat Disord. 2019 Apr 11. pii: S1353-8020(19)30205-6. doi: 10.1016/j.parkreldis.2019.04.010. [Epub ahead of print]

PMID:
31003905
12.

Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults.

Creese B, Brooker H, Ismail Z, Wesnes KA, Hampshire A, Khan Z, Megalogeni M, Corbett A, Aarsland D, Ballard C.

Am J Geriatr Psychiatry. 2019 Aug;27(8):823-834. doi: 10.1016/j.jagp.2019.01.215. Epub 2019 Feb 2.

PMID:
30902566
13.

Metabolic patterns across core features in dementia with lewy bodies.

Morbelli S, Chincarini A, Brendel M, Rominger A, Bruffaerts R, Vandenberghe R, Kramberger MG, Trost M, Garibotto V, Nicastro N, Frisoni GB, Lemstra AW, van der Zande J, Pilotto A, Padovani A, Garcia-Ptacek S, Savitcheva I, Ochoa-Figueroa MA, Davidsson A, Camacho V, Peira E, Arnaldi D, Bauckneht M, Pardini M, Sambuceti G, Aarsland D, Nobili F.

Ann Neurol. 2019 May;85(5):715-725. doi: 10.1002/ana.25453. Epub 2019 Mar 22.

PMID:
30805951
14.

Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases.

Babiloni C, Del Percio C, Pascarelli MT, Lizio R, Noce G, Lopez S, Rizzo M, Ferri R, Soricelli A, Nobili F, Arnaldi D, Famà F, Orzi F, Buttinelli C, Giubilei F, Salvetti M, Cipollini V, Franciotti R, Onofrj M, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Aarsland D, Parnetti L, Farotti L, Marizzoni M, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Yener G, Emek-Savaş DD, Triggiani AI, Taylor JP, McKeith I, Stocchi F, Vacca L, Hampel H, Frisoni GB, De Pandis MF, Bonanni L.

Neurobiol Aging. 2019 May;77:112-127. doi: 10.1016/j.neurobiolaging.2019.01.013. Epub 2019 Jan 24.

PMID:
30797169
15.

Glial activation and inflammation along the Alzheimer's disease continuum.

Nordengen K, Kirsebom BE, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, Torsetnes SB, Grøntvedt GR, Waterloo KK, Aarsland D, Nilsson LNG, Fladby T.

J Neuroinflammation. 2019 Feb 21;16(1):46. doi: 10.1186/s12974-019-1399-2.

16.

Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies.

Moylett S, Price A, Cardinal RN, Aarsland D, Mueller C, Stewart R, O'Brien JT.

J Alzheimers Dis. 2019;67(3):995-1005. doi: 10.3233/JAD-180877.

PMID:
30776008
17.

Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia.

Giil LM, Solvang SH, Giil MM, Hellton KH, Skogseth RE, Vik-Mo AO, Hortobágyi T, Aarsland D, Nordrehaug JE.

J Alzheimers Dis. 2019;68(1):239-253. doi: 10.3233/JAD-181131.

PMID:
30775974
18.

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease.

Ashton NJ, Nevado-Holgado AJ, Barber IS, Lynham S, Gupta V, Chatterjee P, Goozee K, Hone E, Pedrini S, Blennow K, Schöll M, Zetterberg H, Ellis KA, Bush AI, Rowe CC, Villemagne VL, Ames D, Masters CL, Aarsland D, Powell J, Lovestone S, Martins R, Hye A.

Sci Adv. 2019 Feb 6;5(2):eaau7220. doi: 10.1126/sciadv.aau7220. eCollection 2019 Feb.

19.

The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over.

Brooker H, Wesnes KA, Ballard C, Hampshire A, Aarsland D, Khan Z, Stenton R, Megalogeni M, Corbett A.

Int J Geriatr Psychiatry. 2019 Jul;34(7):932-940. doi: 10.1002/gps.5085. Epub 2019 Feb 28.

PMID:
30746778
20.

Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort.

Selvackadunco S, Langford K, Shah Z, Hurley S, Bodi I, King A, Aarsland D, Troakes C, Al-Sarraj S.

J Neural Transm (Vienna). 2019 Mar;126(3):327-337. doi: 10.1007/s00702-018-01967-w. Epub 2019 Feb 7.

21.

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.

Green H, Tsitsi P, Markaki I, Aarsland D, Svenningsson P.

CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x. Review.

22.

The kynurenine pathway and cognitive performance in community-dwelling older adults. The Hordaland Health Study.

Solvang SH, Nordrehaug JE, Tell GS, Nygård O, McCann A, Ueland PM, Midttun Ø, Meyer K, Vedeler CA, Aarsland D, Refsum H, Smith AD, Giil LM.

Brain Behav Immun. 2019 Jan;75:155-162. doi: 10.1016/j.bbi.2018.10.003. Epub 2018 Oct 25.

PMID:
30675874
23.

Prevalence of late-life depression and gap in mental health service use across European regions.

Horackova K, Kopecek M, Machů V, Kagstrom A, Aarsland D, Motlova LB, Cermakova P.

Eur Psychiatry. 2019 Apr;57:19-25. doi: 10.1016/j.eurpsy.2018.12.002. Epub 2019 Jan 15.

PMID:
30658276
24.

The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS).

Husebø BS, Ballard C, Aarsland D, Selbaek G, Slettebo DD, Gulla C, Aasmul I, Habiger T, Elvegaard T, Testad I, Flo E.

J Am Med Dir Assoc. 2019 Mar;20(3):330-339. doi: 10.1016/j.jamda.2018.11.006. Epub 2019 Jan 7.

PMID:
30630722
25.

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.

Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, Zetterberg H, Hye A.

Acta Neuropathol Commun. 2019 Jan 9;7(1):5. doi: 10.1186/s40478-018-0649-3.

26.

Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies.

Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, Smith L, Basso C, Stewart R, Ballard C, O'Brien JT, Aarsland D, Stubbs B, Veronese N.

Ageing Res Rev. 2019 Mar;50:72-80. doi: 10.1016/j.arr.2019.01.005. Epub 2019 Jan 6. Review.

PMID:
30625375
27.

Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.

Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hägg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Brækhus A, Bråthen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbæk G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D.

Nat Genet. 2019 Mar;51(3):404-413. doi: 10.1038/s41588-018-0311-9. Epub 2019 Jan 7.

PMID:
30617256
28.

In Brief Neuropsychological Assessment, Amnestic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion.

Hessen E, Kirsebom BE, Eriksson CM, Eliassen CF, Nakling AE, Bråthen G, Waterloo KK, Aarsland D, Fladby T.

J Alzheimers Dis. 2019;67(2):715-723. doi: 10.3233/JAD-180964.

29.

Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci.

Witoelar A, Rongve A, Almdahl IS, Ulstein ID, Engvig A, White LR, Selbæk G, Stordal E, Andersen F, Brækhus A, Saltvedt I, Engedal K, Hughes T, Bergh S, Bråthen G, Bogdanovic N, Bettella F, Wang Y, Athanasiu L, Bahrami S, Le Hellard S, Giddaluru S, Dale AM, Sando SB, Steinberg S, Stefansson H, Snaedal J, Desikan RS, Stefansson K, Aarsland D, Djurovic S, Fladby T, Andreassen OA.

Sci Rep. 2018 Dec 27;8(1):18088. doi: 10.1038/s41598-018-36429-6.

30.

Cognitive Interventions in Parkinson's Disease: Where We Want to Go within 20 Years.

Kalbe E, Aarsland D, Folkerts AK.

J Parkinsons Dis. 2018;8(s1):S107-S113. doi: 10.3233/JPD-181473.

31.

Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease.

Kirsebom BE, Nordengen K, Selnes P, Waterloo K, Torsetnes SB, Gísladóttir B, Brix B, Vanmechelen E, Bråthen G, Hessen E, Aarsland D, Fladby T.

Alzheimers Dement (N Y). 2018 Nov 10;4:617-627. doi: 10.1016/j.trci.2018.10.003. eCollection 2018.

32.

The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease.

FitzGerald JM, Perera G, Chang-Tave A, Price A, Rajkumar AP, Bhattarai M, O'Brien JT, Ballard C, Aarsland D, Stewart R, Mueller C.

J Am Med Dir Assoc. 2019 May;20(5):604-609. doi: 10.1016/j.jamda.2018.09.021. Epub 2018 Nov 15.

PMID:
30448339
33.

An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults.

Brooker H, Wesnes KA, Ballard C, Hampshire A, Aarsland D, Khan Z, Stenton R, McCambridge L, Corbett A.

Int J Geriatr Psychiatry. 2019 Jul;34(7):921-931. doi: 10.1002/gps.5033. Epub 2019 May 16.

PMID:
30443984
34.

A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium.

Oppedal K, Ferreira D, Cavallin L, Lemstra AW, Ten Kate M, Padovani A, Rektorova I, Bonanni L, Wahlund LO, Engedal K, Nobili F, Kramberger M, Taylor JP, Hort J, Snædal J, Blanc F, Walker Z, Antonini A, Westman E, Aarsland D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Mar;15(3):400-409. doi: 10.1016/j.jalz.2018.09.011. Epub 2018 Nov 12.

PMID:
30439333
35.

Amyloid-β and Parkinson's disease.

Lim EW, Aarsland D, Ffytche D, Taddei RN, van Wamelen DJ, Wan YM, Tan EK, Ray Chaudhuri K; Kings Parcog groupMDS Nonmotor study group.

J Neurol. 2018 Oct 30. doi: 10.1007/s00415-018-9100-8. [Epub ahead of print] Review.

PMID:
30377818
36.

Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinson's Disease.

Karlstedt M, Fereshtehnejad SM, Aarsland D, Lökk J.

Parkinsons Dis. 2018 Sep 16;2018:9548681. doi: 10.1155/2018/9548681. eCollection 2018.

37.

Investigating the relationship between age of onset of depressive disorder and cognitive function.

Eraydin IE, Mueller C, Corbett A, Ballard C, Brooker H, Wesnes K, Aarsland D, Huntley J.

Int J Geriatr Psychiatry. 2019 Jan;34(1):38-46. doi: 10.1002/gps.4979. Epub 2018 Sep 27.

PMID:
30259558
38.

Cognition among individuals along a spectrum of increased risk for Parkinson's disease.

Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative.

PLoS One. 2018 Aug 20;13(8):e0201964. doi: 10.1371/journal.pone.0201964. eCollection 2018.

39.

Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies.

Breitve MH, Brønnick K, Chwiszczuk LJ, Hynninen MJ, Aarsland D, Rongve A.

Alzheimers Res Ther. 2018 Aug 18;10(1):83. doi: 10.1186/s13195-018-0416-5.

40.

Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease.

Vik-Mo AO, Bencze J, Ballard C, Hortobágyi T, Aarsland D.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):728-730. doi: 10.1136/jnnp-2018-318445. Epub 2018 Jul 27. No abstract available.

PMID:
30054314
41.

Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.

Chai YL, Chong JR, Weng J, Howlett D, Halsey A, Lee JH, Attems J, Aarsland D, Francis PT, Chen CP, Lai MKP.

Brain Pathol. 2019 Jan;29(1):63-74. doi: 10.1111/bpa.12631. Epub 2018 Oct 17.

PMID:
30051532
42.

Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Mueller C, Rajkumar AP, Wan YM, Velayudhan L, Ffytche D, Chaudhuri KR, Aarsland D.

CNS Drugs. 2018 Jul;32(7):621-635. doi: 10.1007/s40263-018-0540-6.

PMID:
30027401
43.

Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study.

Vik-Mo AO, Giil LM, Ballard C, Aarsland D.

Int J Geriatr Psychiatry. 2018 Oct;33(10):1361-1369. doi: 10.1002/gps.4933. Epub 2018 Jul 6.

PMID:
29979473
44.

Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.

Giil LM, Aarsland D, Hellton K, Lund A, Heidecke H, Schulze-Forster K, Riemekasten G, Vik-Mo AO, Kristoffersen EK, Vedeler CA, Nordrehaug JE.

J Alzheimers Dis. 2018;64(3):761-774. doi: 10.3233/JAD-170882.

PMID:
29914018
45.

Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM).

Erdal A, Flo E, Aarsland D, Selbaek G, Ballard C, Slettebo DD, Husebo BS.

Clin Interv Aging. 2018 May 16;13:935-946. doi: 10.2147/CIA.S161052. eCollection 2018.

46.

Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications.

Mueller C, Perera G, Rajkumar AP, Bhattarai M, Price A, O'Brien JT, Ballard C, Stewart R, Aarsland D.

Alzheimers Dement (Amst). 2017 Dec 27;10:143-152. doi: 10.1016/j.dadm.2017.12.001. eCollection 2018.

47.

Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM).

Erdal A, Flo E, Aarsland D, Ballard C, Slettebo DD, Husebo BS.

Drugs Aging. 2018 Jun;35(6):545-558. doi: 10.1007/s40266-018-0546-2.

48.

Risk factors for non-motor symptoms in Parkinson's disease.

Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ.

Lancet Neurol. 2018 Jun;17(6):559-568. doi: 10.1016/S1474-4422(18)30127-3. Epub 2018 Apr 23. Review.

PMID:
29699914
49.

Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials.

Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B.

Mov Disord. 2018 Apr;33(4):528-536. doi: 10.1002/mds.27355. Review.

PMID:
29624752
50.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787

Supplemental Content

Loading ...
Support Center